R&D | February 24, 2026
Promise Bio launches frontier Epiproteomic Innovation Grant to supercharge biotech R&D
The program offers selected participants advanced access to Promise Bio’s broad-epiproteomic platform
The program offers selected participants advanced access to Promise Bio’s broad-epiproteomic platform
This partnership represents a systemic shift from awareness to large-scale action for 57 lakh children
Under the deal, Quiver will receive an undisclosed advance payment and research support
To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia
The study will test the company’s lead product, ZI-MA4-1, in patients with advanced solid cancers
The funding comes under the AHG Catalysing Innovation Awards, part of the Addiction Healthcare Goals programme led by the Office for Life Sciences
UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies
The alliance directly links VivaMed’s computational drug hypotheses with Syngene’s preclinical development capabilities
The project entails a total planned capital expenditure of approximately Rs. 500 - 520 crore
The clinical program has benefited from extensive European Union support, including the IMI2 TRIC-TB and UNITE4TB projects, as well as funding from the EDCTP2 bEto-TB project
Subscribe To Our Newsletter & Stay Updated
